Low-dose aspirin – benefits in ET?

Does low-dose aspirin offer benefits for people with “low-risk” essential thrombocythaemia (ET)? Researchers in Spain have written an article suggesting that low-dose aspirin may particularly benefit people with ET if they have the JAK2V617F mutation or cardiovascular risk factors. Dr Claire Harrison of Guy’s and St Thomas’ Hospital (UK) and Dr Tiziano Barbui of the Division of Hematology, Ospedali Riuniti di Bergamo in Bergamo, Italy offer commentary on this article about aspirin and MPDs.